FTI ValueNav: Next-Generation Commercial Forecasting
Engine for Drugs in Early Development
-
July 31, 2026
-
FTI ValueNav helps life sciences companies and investors understand how a drug in early development may perform in the market. It uses proprietary data, economic modeling and machine learning to estimate how quickly a drug may be adopted and what its price could be.
Our teams can also test how changes in a drug’s effectiveness, safety, delivery method or competitive landscape may affect its commercial potential.
These insights can help validate revenue forecasts, support portfolio prioritization and investment decisions, inform pricing and market access strategy, and enhance M&A evaluation and commercial due diligence.
To learn how FTI ValueNav can provide an earlier, data-driven view of an asset’s potential, click here to read more.
Published
July 31, 2026
Key Contacts
Senior Managing Director
Senior Director
Senior Consultant